

Special Issue

Feature Review Papers on β -Lactam and β -Lactam- β -Lactamase Inhibitor Combinations and Resistance Mechanisms to β -Lactam and β -Lactam- β -Lactamase Inhibitor Combinations

Message from the Guest Editors

The description of the topic: β -Lactam and β -lactamase inhibitors are the safest and most commonly prescribed class of antibiotics. Over the last decade, great progress has been made in combating the emergence of β -lactam resistance in Gram-negative pathogens. Moreover, highly β -lactam-resistant pathogens continue to emerge in the clinic, challenging our current diagnostics as well as treatment strategies. The goal of this Special Issue is to gather the world's leading experts in the field and provide the readership with a collection of focused review articles regarding these topics. Review articles regarding β -lactam agents, resistance mechanisms that lead to β -lactam resistance, as well as reviews concerning clinical challenges and diagnostic tools are welcomed.

Guest Editors

Dr. Krisztina M. Papp-Wallace

Dr. Maria Fernanda Mojica

Dr. Clyde Smith

Dr. Philip Hinchliffe

Dr. Khalid Dousa

Deadline for manuscript submissions

closed (31 October 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/121939

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)